{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-030701","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.057124+00:00","generated_at":"2026-05-17T13:54:28.675671+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PDS Biotech reports Q2 net loss $9.4M, clinical updates on PDS0101 and PDS01ADC","bullets":["Net loss $9.4M ($0.21/dil share) vs $8.3M ($0.23) in Q2 2024.","R&D $4.2M, G&A $3.4M; total operating expenses $7.6M vs $8.7M.","Cash $31.9M (6/30/25) vs $41.7M (12/31/24); net interest expense $1.8M vs $0.5M.","Colorectal cancer cohort of Phase 2 trial with PDS01ADC met expansion criteria (≥6 of 9 objective responses).","Phase 3 VERSATILE-003 trial for PDS0101 in HPV16+ HNSCC progressing; 3 ASCO 2025 abstracts presented."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-030701","json":"https://secwatch.observer/filing/0001140361-25-030701.json","markdown":"https://secwatch.observer/filing/0001140361-25-030701.md","text":"https://secwatch.observer/filing/0001140361-25-030701.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036125030701/0001140361-25-030701-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036125030701/ef20053853_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:54:28.675671+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}